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A B S T R A C T
Background: Dopaminergic loss on 123I-Ioflupane brain imaging is a recognised biomarker for dementia with
Lewy bodies. It is usually assessed using a visual rating scale developed for Parkinson's disease, which may not be
optimal for dementia with Lewy bodies, as patterns of dopaminergic loss can be different.
Objectives: We aimed to develop a new visual rating scale for 123I-Ioflupane brain images in Lewy body disease
that encompasses appearances seen in dementia with Lewy bodies, and validate this against autopsy diagnosis.
Methods: Four experienced observers developed and tested a new scale consisting of two metrics, reflecting
overall loss and heterogeneity of loss. 66 subjects were used during development including clinical diagnoses of
Alzheimer's disease (n=14), Parkinson's disease (n=9), Parkinson's disease dementia (n= 9), dementia with
Lewy bodies (n=15) and normal controls (n=19). The scale was then tested on an independent group of 46
subjects with autopsy confirmed diagnosis: Alzheimer's disease (n=11), Parkinson's disease (n=3), Parkinson's
disease dementia (n=15), dementia with Lewy bodies (n=12), normal controls (n=4) and Frontotemporal
dementia (n= 1).
Results: In the autopsy validation the sensitivity and specificity of the new scale for Lewy body disease was 97%
and 100% respectively, compared with the standard scale which had the same sensitivity (97%), but lower
specificity (80%). The new scale had excellent inter rater reliability (intra-class correlation coefficient 0.93).
Conclusion: A new robust and reliable rating scale is described that straightforwardly captures the visual ap-
pearance of 123I-Ioflupane brain images. It demonstrated high accuracy in autopsy confirmed cases and offers
advantages over the existing visual rating scale.
1. Introduction
Dementia with Lewy bodies (DLB) is the second commonest cause of
degenerative dementia after Alzheimer's disease (AD) (Vann Jones and
O'Brien, 2014). Although clinical criteria for DLB have high accuracy in
specialist centres (sensitivity and specificity both>80%) (McKeith
et al., 2005), it may be low in non-specialist centres. Correct diagnosis
of dementia is vital to communicate prognosis to patients and carers
and to avoid unnecessary and potentially harmful treatments. Visuali-
sation of nigrostriatal dopaminergic integrity using 123I-Ioflupane (FP-
CIT, DaTSCAN, GE Healthcare) brain SPECT imaging has been reported
to improve sensitivity in probable DLB (McKeith et al., 2007), to in-
crease certainty of diagnosis in possible DLB (Walker et al., 2015) and is
included as an “indicative biomarker” in recent diagnostic criteria
(McKeith et al., 2017).
Clinical reporting 123I-Ioflupane scans for DLB is most often by
primary visual read which may be supported by semi-quantification. It
is helpful to have a systematic robust method to do this visual assess-
ment. A visual rating scale was introduced by Benamer (Benamer et al.,
2000) and developed and validated for Parkinson's disease (PD). When
applied in DLB (e.g. (McKeith et al., 2007)), this scale has limitations, in
particular the scale does not include a pattern of uniform reduction
which may be more common in DLB (O'Brien et al., 2004; Walker et al.,
2004). Anecdotally, within our centre it was apparent that observers
were having to force images into Benamer categories, even though the
image did not fit the strict definition.
Kahraman et al. (2012) and Davidsson et al. (2014) employed a
system of visual assessment which was similar to Benamer, except that
different image categories were defined. Those studies found some
success with this system to distinguish PD from atypical PD syndromes,
although they did not directly compare with the Benamer method. The
application in those papers was different to ours and so unlikely to be
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directly applicable, particularly as they did not include a category of
moderate generalised loss which may be seen in DLB.
Visual reading is likely to remain a principal mode of assessment
due to difficulties in image quantification. Absolute quantification of
123I-FP-CIT SPECT is extremely difficult (Bailey and Willowson, 2013)
and therefore semi-quantitative regional analysis is usually employed.
Although useful, there are several limitations to this approach. Different
methods of semi-quantification exist with no standard approach (Koch
et al., 2005; Morton et al., 2005a, 2005b; Poli et al., 2013; Slomka et al.,
2001; Tossici-Bolt et al., 2006, 2011, 2017; Varrone et al., 2013). De-
pending on the method used, specific binding ratios may be sensitive to
changes in acquisition and processing (Dickson et al., 2010; Koch et al.,
2013, 2014; Tossici-Bolt et al., 2011; Tossici-Bolt et al., 2017). Deriving
a suitable local normal range for binding ratios can be problematic
(Dickson et al., 2017). Image warping and registration may not fully
account for anatomical variations in striatal shape. Quantification may
give misleading answers in cases where background is low due to
atrophy or artefactually high due to scalp uptake.
Our aim in the current work was to develop a new visual rating scale
in Lewy body disease (LBD) that encompasses the pattern and dis-
tribution of dopaminergic loss seen in DLB. We wished the new scale to
be reproducible, straightforward to implement, capture both the overall
uptake and its distribution and be highly accurate in separating LBD
from non-LBD cases in a mixed group of cases including a significant
proportion with DLB. Our aim was to devise a system that did not rely
on assigning images to pre-defined categories, but that would be ap-
plicable across the full range of conditions for which 123I-FP-CIT
SPECT is used, including DLB. The scale was developed using a group of
subjects with robust clinical diagnoses and then tested using in-
dependent cases that additionally had proceeded to autopsy confirma-
tion of diagnosis. The new scale was compared to the existing Benamer
scale.
2. Materials and methods
Based on our expertise in rating Ioflupane scans and in particular
the need to capture balanced loss in DLB we devised a new rating
method which we will refer here to as the “Newcastle scale”. Data from
well characterised subjects (O'Brien et al., 2004) were used for the
development and testing of the scale in two phases. Phase one consisted
of applying it to cases with clinical diagnoses and setting a threshold for
detection of Lewy body disease. In phase two the scale was tested using
an independent group of subjects with autopsy diagnosis.
All procedures performed in studies involving human participants
were in accordance with NHS and Newcastle Brain Bank ethical ap-
provals and with the 1964 Helsinki declaration and its later amend-
ments or comparable ethical standards. Informed consent was obtained
from all individual participants included in the study.
2.1. Subjects
Image data was drawn from subjects involved in a previous study
(O'Brien et al., 2004) as shown in Tables 1 and 2. Patients were ob-
tained from a community-dwelling population referred to local old age
psychiatry and neurology services. Normal controls were recruited from
among friends and spouses of patients included in this and other re-
search studies.
Subjects underwent detailed physical, neurological and neu-
ropsychiatric examinations, including the Mini-Mental State
Examination (MMSE) (Roth et al., 1986), and the motor subsection of
the Unified Parkinson's Disease Rating Scale (UPDRS III) (Fahn, 1987).
Diagnosis was made by a consensus panel of experienced dementia
clinicians using the NINCDS/ADRDA criteria for AD (McKhann et al.,
1984), the consensus criteria for DLB and PDD (Parkinson's disease
dementia) (McKeith et al., 1996) and the UK Parkinson's Disease So-
ciety Brain Bank criteria for PD (Gibb and Lees, 1988). All AD subjects
met criteria for probable AD, 23 DLB subjects fulfilled probable and 4
possible DLB. No subject was on any medication which may affect 123I-
Ioflupane uptake.
Forty-six subjects underwent autopsy and neuropathological as-
sessment which was performed blind to clinical diagnoses and 123I-
Ioflupane findings. The mean (sd) time between scan and autopsy was
5.74 (3.74) years. Neuropathological findings in these cases have been
described previously (Thomas et al., 2017). Six cases fulfilled the
neuropathological criteria for both AD and DLB (mixed dementia). In
these cases clinical notes were reviewed at baseline and all follow up
(blinded to any 123I-Ioflupane results) and the most likely clinical di-
agnosis at the time of scan was chosen to validate the 123I-Ioflupane
results.
In phase one Lewy body disease refers to cases with a clinical di-
agnosis of PD, PDD or DLB. In phase two this term refers to subjects
with Lewy body disease meeting neuropathological criteria (Thomas
et al., 2017). This includes subjects with a previous clinical diagnosis of
PD, PDD or DLB and who had significant Lewy body pathology at au-
topsy. Since PD, PDD and DLB may be indistinguishable pathologically,
we have classified these subjects according to their final combined
clinicopathological diagnoses where LBD is confirmed at autopsy.
2.2. Imaging
Subjects were imaged using a triple-detector rotating gamma
camera (Picker 3000XP) fitted with a high resolution fan-beam colli-
mator, 4 h after injection of 150MBq of 123I-Ioflupane. One hundred
and twenty 15 s views over a 360° orbit were acquired on a 128×128
matrix with a square pixel dimension of 3.5mm. Imaging time was
30min. Image reconstruction was performed without attenuation cor-
rection using filtered back projection with a Butterworth filter (order
13, cut-off 0.3 cycles.cm−1) to produce transverse sections with an axial
resolution of 10mm full width at half maximum (FWHM).
Table 1
Subjects used in phase 1 (clinical diagnoses).
n Sex (M:F) Age MMSE UPDRS III
Controls 19 11:8 73.1 ± 6.0 28.4 ± 1.3 0.5 ± 0.8
AD 14 5:9 80.9 ± 5.3 17.1 ± 5.2 6.1 ± 6.3
DLB 15 9:6 75.2 ± 7.1 14.7 ± 5.6 31.1 ± 10.9
PD 9 7:2 75.2 ± 5.2 25.9 ± 2.3 25.3 ± 10.2
PDD 9 7:2 73.0 ± 7.7 19.9 ± 6.2 42.0 ± 14.3
Group tests, statistic, p-value χ2= 5.8, 0.2 F4,61= 3.7, 0.009 F4,61= 26.9, < 0.001 H4= 53.0, < 0.001
Pair wise tests Gabriel's post-hoc tests: Gabriel's post-hoc tests: Mann-Whitney post-hoc tests:
ns=not significant (p > 0.05). AD > con, p <0.04 Con, PD > AD, DLB, PDD (p <0.04);
Otherwise ns.
Con, AD < DLB, PD, PDD (p < 0.02);
Otherwise nsAD > PDD, p <0.04
Otherwise ns
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2.3. Rating and scale development
Four observers were involved at both phases. All observers had
experience of research involving 123I-Ioflupane imaging in the context
of DLB diagnosis, although not all were imaging specialists. AT is a
consultant old age psychiatrist with over 20 years experience of re-
search and clinical practice relating to DLB, but is not involved with
clinical reporting. JJL is a consultant medical physicist and expert in
image analysis who provides some limited clinical reporting. GP is a
consultant radiologist with particular interest in neurological applica-
tions and provides a full range of expert independent clinical reports.
PD is and an old age psychiatry specialist registrar with 5 years ex-
perience in research relating to DLB and imaging who does not provide
any image reports.
In compiling the Newcastle scale we aimed to overcome two fun-
damental assumptions of the standard Benamer scale, devised for PD,
which are: a) that when dopaminergic loss occurs it is initially uni-
lateral and, b) that dopaminergic loss invariably occurs with a pre-
dictable rostro-caudal gradient, putamen loss always occurring before
caudate. This is because previous work has shown that in DLB and PDD
dopaminergic loss is much more often both bilateral and uniform than
in PD (O'Brien et al., 2004; Walker et al., 2004).
The Newcastle scale considers separately uptake scores in four areas
(left and right caudate and putamen) relative to background and then
derives two summary metrics, a total loss score (sum of all areas, with
higher values indicating more severe abnormality) and a difference score
(maximum difference between any two areas). Individual area uptake
scores vary between 0 (normal) and 3 (absent) with a value of 0.5 in-
dicating very mild or equivocal loss. Details are given below and ex-
ample images and scores are shown in Fig. 1.
In phase one each rater independently blindly rated each subject
using the Newcastle scale and the median total and difference scores for
all raters were determined. These scores were compared to clinical di-
agnosis and based on these results, a threshold for abnormality (i.e. the
presence of Lewy body disease) was set. In phase two, the process was
repeated and using the threshold set in phase one, the results were
compared to the final autopsy diagnoses.
In addition for both phases images were rated according to the
Benamer scale (Benamer et al., 2000). As noted above, certain images
(e.g. Fig. 1e) do not strictly fit within the categories defined by this
scale. In these cases raters recorded the pattern of uptake (e.g. sig-
nificant moderate global reduction) and then allocated a forced “best
fit” Benamer category.
2.4. Details of scoring procedure
1. Use a standard colour scale (GE) with the highest uptake at 100%
and the bottom of scale at 0%
2. Assess background counts as: normal, very mildly raised, mildly
raised, moderately or highly raised
3. Consider separately each of the following structures: Right Caudate,
Right Putamen, Left Caudate and Left Putamen
4. Locate the structure with highest uptake and grade this with re-
ference to the background as shown below:
0-Normal (i.e. normal background)
0.5-Very mild /equivocal loss (i.e. very mildly raised background)
1-Mild loss (i.e. mildly raised background)
2-Moderate loss (i.e. moderately raised background)
3-Severe loss (i.e. highly raised background)
Note: To be classed as normal the structure should have a crisp
uniform edge and have normal thickness. In cases where the mean
uptake appears normal, but the structure is irregular in some way,
“ragged”, or with a clipped edge, then a score of 0.5 should be used
5. Grade remaining structures taking into account the highest uptake
structure and background
6. Derive two metrics as follows:
Total score= Sum of the grades for all four areas.
Difference score=Maximum difference in grade between any two
areas.
2.5. Statistical analysis
Statistical analysis was carried out using SPSS (v23, IBM). Inter
operator agreement for the Newcastle scale was measured used the
intra-class correlation coefficient (ICC, two-way mixed effects models)
for each striatal region (right caudate, right putamen, left caudate, left
putamen) as well as for the total score. The optimum threshold to
maximise the combined sensitivity and specificity for Lewy body dis-
ease detection was determined in phase one using ROC curve analysis.
3. Results
3.1. Accuracy
Median scores versus clinical diagnosis for phase one are shown in
Fig. 2. The total score provided a larger separation between those with
and without Lewy Body disease than the difference score. ROC curve
analysis (phase one) identified a total score value of 4.5 as providing
the highest combined sensitivity and specificity. Defining abnormality
in this way as a total median score of> 4 gave a Lewy Body disease
sensitivity of 28/33 (85%) and specificity of (31/33) 94%. The overall
misclassification rate was 7/66 (11%).
Including the difference score or left/right or anterior/posterior
score asymmetry did not improve the accuracy within phase one.
Table 2
Subjects used for phase 2 (autopsy diagnoses).
n Sex (M:F) Age MMSE UPDRS III
Control 4 2: 2 81.3 ± 7.4 28.0 ± 2.2 3.3 ± 3.2
AD 11 7: 4 80.4 ± 4.6 17.2 ± 4.7 8.5 ± 7.7
DLB 12 7: 5 75.6 ± 6.3 18.5 ± 5.2 22.2 ± 14.5
PD 3 3: 0 81.4 ± 3.4 25.7 ± 5.0 39.7 ± 19.9
PDD 15 11: 4 71.1 ± 4.7 21.1 ± 5.6 34.9 ± 11.4
Frontotemporal dementia (FTD) 1 1: 0 78.4 25.0 4.0
Group tests, Statistic, p-value (Performed on all groups
except FTD and PD)
χ2= 1.1, 0.8 F3,38= 7.7, < 0.001 F3,38= 5.0, 0.005 F3,38= 15.7, < 0.001
Pair-wise tests Gabriel's Post-Hoc tests Gabriel's post-hoc tests Mann-Whitney post-hoc tests
ns=not significant Con, AD > PDD
(p < 0.007)
Con > AD, DLB
(p < 0.01)
DLB, PDD > Con, AD
(p < 0.03);
P > 0.05 Otherwise ns Otherwise ns PDD > DLB (p=0.03)
Otherwise ns
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Median scores versus autopsy diagnosis for phase two are shown in
Fig. 3. Using the Newcastle scale (and threshold as described above) the
sensitivity and specificity for Lewy body disease was 30/31 (97%) and
15/15 (100%) respectively (i.e. just one false negative case, with a total
and difference score of 0).
In phase one the Benamer scale sensitivity and specificity both had a
value of 28/33 (85%). In phase two using the Benamer scale gave
sensitivity and specificity of 30/31 (97%) and 12/15 (80%) respectively
(i.e. one false negative case and three false positive cases). For phase
two, The Newcastle scale gave the same sensitivity (97%) as the
Benamer scale and improved specificity (100% vs 80%), although this
difference just failed to reach statistical significance (p=0.07).
3.2. Scale applicability and inter-operator reliability
For the Newcastle scale, results from phase one and two were
combined (n=112) and the ICC values were: 0.83, 0.94, 0.81, 0.92 and
0.93, for the right caudate, right putamen, left caudate, left putamen
and total scores respectively. This represents ‘good to excellent’ inter-
rater reliability (Koo and Li, 2016).
In phase two, there were 11 cases in which the Benamer scale was
not strictly applicable, that is the image appearance did not fit with any
of the categories of that scale. Seven cases were described as “very mild
global loss”, of these five were controls, one was AD, and one was DLB;
these cases were all allocated to Benamer category 0 as the forced “best-
fit”. Four cases were described as having “significant moderate global
loss” and all had clinical DLB diagnoses; these cases were all allocated
to Benamer category 1 as the forced “best-fit”.
For phase one and two combined the categories defined in the ori-
ginal Benamer scale (Benamer et al., 2000) were applicable in 90/112
(80%) of cases. Of these cases there was complete rater agreement in
44/90 (49%) and a majority agreement in 39/90 (43%). If PD and PDD
cases were excluded then the Benamer scale was applicable in 56/77
Fig. 1. Example images illustrating application of
the Newcastle scale. From left to right, top to bottom:
a) Normal subject Score 0,0,0,0 Total
0 Difference 0
b) Normal subject Score 0.5,0.5,0.5,1 Total
2.5 Difference 0.5
c) DLB patient Score 1,2,1,1 Total 5 Difference 1
d) PD patient Score 1,3,1,3 Total 8 Difference 2
e) DLB patient Score 2,2,1,2 Total 7 Difference 1
f) PDD patient Score 2,3,2,3 Total 10 Difference 1
Fig. 2. Median rater total and difference scores for subjects in phase one. (A
small random jitter has been applied to separate overlying points).
Fig. 3. Median rater total and difference scores for subjects in phase two. (A
small random jitter has been applied to separate overlying points).
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(73%) of cases (phase one and two).
4. Discussion
A method of visual rating is presented which in this relatively small
study was highly accurate for Lewy body disease diagnosis in autopsy
proven cases. The method was straightforward to apply and had ex-
cellent observer agreement. Although the group size in each phase was
relatively small, the abnormality threshold was determined in one
phase and then tested on independent autopsy validated cases. This
approach gives a more robust assessment of the scale performance than
using a single group of subjects to develop and test the scale.
The aim was to devise a system that would be applicable for use in
clinical and research applications relating to DLB. However, DLB is
within spectrum of Lewy body diseases involving nigrostriatal dopa-
minergic dysfunction having similar pathophysiology and clinical
management. We therefore did not seek to distinguish between subjects
within this spectrum, but aimed to produce a scale that would accom-
modate all potential appearances within this group and provide a dis-
tinction with subjects not having Lewy body disease. Clinically distin-
guishing between AD and DLB especially in early stages is a far more
pertinent question that distinguishing between DLB and PDD. One
could devise separate scales to be applicable in different applications,
such as a dementia scale and a PD scale, but given the pathophysiolo-
gical overlap a single scale accommodating the full spectrum of ap-
pearances is more desirable. In order to develop and test this scale a
wide range of conditions including DLB was employed.
4.1. Accuracy
The important difference between phases one and two is that the
latter benefited from autopsy validation and so whilst in phase one,
three AD cases were reported as abnormal (Fig. 2) in phase two, no AD
cases were reported as abnormal and all abnormal 123I-Ioflupane scans
had Lewy body disease. In phase one, there were 7/66 misclassified
cases. Two cases initially diagnosed as ‘possible’ PD had normal 123I-
Ioflupane scans. Their baseline UPDRS III scores were 16 and 19 re-
spectively, which didn't progress at one year, while their motor phe-
notypes were tremor dominant. It seems likely that these patients had
essential tremor rather than PD. Three patients with an initial clinical
diagnosis of DLB had normal 123I-Ioflupane scans. Review after one year
suggested that these patients were likely to have had AD. Two patients
initially diagnosed as AD had borderline high scores on the Newcastle
Scale; on review with follow up there was a suggestion of AD with
developing parkinsonism (UPDRS scores increasing from 13 to 28 and 8
to 19 after one year) and so these may have been mixed AD plus DLB
cases.
In phase two, where diagnosis was confirmed at autopsy, all cases
were correctly classified using the Newcastle scale apart from one DLB
patient who had a normal scan. The neuropathological summary states:
“Neuropathological examination revealed AD and DLB (mixed de-
mentia) as well as an old infarct in the right rostral striatum.” For this
patient, the mean activity ratio for the posterior putamen (as described
in (O'Brien et al., 2004) was 2.74, which is closer to the average for
controls and AD patients (3.2+/−0.54 and 3.01+/−0.52 respec-
tively) rather than DLB patients (1.92+/−0.68). On the Benamer
scale all raters scored this patient as 0. This case, together with two
others from a larger study (Thomas et al., 2017), provides evidence that
it is possible to have DLB without nigrostriatal dopaminergic loss and
therefore false negative cases will arise whatever analysis method is
used.
Overall in phase 2 there were 10 (22%) cases where the neuro-
pathological diagnoses differed from the consensus clinical diagnosis at
the time of the initial study (O'Brien et al., 2004), although only two
cases where the change reversed the presence of any Lewy body dis-
ease. Other studies (Thomas et al., 2017; Walker and Walker, 2009)
have indicated that the accuracy of 123I-Ioflupane is higher compared to
autopsy confirmed diagnosis than to clinical diagnosis. There is there-
fore need for caution when developing rating scales or quantification
methods without autopsy confirmed diagnosis.
4.2. Distribution of uptake
Part of the rationale for the proposed rating method is to enable a
simple visual plot that captures both the total uptake and heterogeneity
of uptake in group studies. This could be useful in a research setting for
initial exploration of the relationship between disease and image ap-
pearance. This is well illustrated in Figs. 2 and 3 and several qualitative
points can be made: 1. for separation into groups with and without
Lewy body disease, total uptake is more important than distribution of
uptake, 2. there is a tendency for uptake to be more uniform in DLB
than PD, although there is a large overlap between these two groups, 3.
completely uniform reduction was not seen in DLB.
In this study using information about the distribution of uptake did
not improve the accuracy of classification into those with and without
Lewy body disease. However, the pattern of nigrostriatal loss in PD is
known to be asymmetric, particularly in early disease (Djang et al.,
2012). Therefore the difference score may potentially be useful in
milder and prodromal cases and this warrants further investigation.
4.3. Comparison to established rating scales
The most established visual rating scale (Benamer et al., 2000), was
developed for Parkinson's disease and may have limitations for DLB. In
particular, it does not include a category for “balanced loss”. We found
that 20% of cases did not fit into any category on the established scale.
Furthermore there was complete agreement among observers on cate-
gory in only 49% of cases. If the PD and PDD cases were excluded then
the number of cases in which the Benamer scale was not applicable rose
to 27%. During discussion about this study and previous ones the au-
thors concluded that they often had to make an arbitrary choice of
Benamer category to describe an uptake appearance.
Kahraman et al. (2012) devised a scale that was similar to that of
Benamer et al. (2000) and found it useful in distinguishing PD from
atypical PD syndromes (APD). Effectively they added one additional
abnormal category, “eagle wing appearance” with normal caudate up-
take and discrete reduction in one or both putamina. The example
image they give of this appearance would fall below the threshold for
abnormality in our study. All of the subjects in that study had clinical
diagnoses of PD or APD and given the relatively low accuracy clinical
compared to pathological diagnosis (Hughes et al., 1992), one might
expect that some of the 165 subjects did not in fact have any cortical
Lewy body disease. However, no subjects were reported as having a
normal image appearance and 12% had the mildly abnormal “eagle
wing” appearance. A strength of the current study is that we included a
wide range of conditions including normal controls and non Lewy Body
disease subjects and in phase two we had autopsy confirmation. This
enabled us to set a threshold for abnormality such that minor image
irregularities can be confidently placed within the normal range. Being
able to distinguish between AD subjects with minor decrease in uptake
and DLB subjects with significantly abnormal scans is clinically very
important. Davidsson et al. (2014) used the same rating scale as that
devised by Kahraman et al. (2012), although only 3 of the 121 subjects
had an image appearance described as “eagle wing” and therefore the
scale applied was very similar to the original Benamer scale in practice.
Although visual rating was useful in that study there were no subjects
with dementia and therefore it is not possible to assess its applicability
in the current context.
4.4. Relevance to clinical practice
In clinical practice it is now common to report based on visual
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assessment with the aid of semi-quantification. However several semi-
quantification methods are available and the optimum thresholds for
abnormality are uncertain. Expert judgement based on visual assess-
ment is still therefore critical. In many cases the decision is clear cut,
but in borderline cases the process of applying the Newcastle scale
provides a useful method to assist the visual evaluation process. It is not
suggested that reporting the total and difference scores explicitly would
be helpful, although certain phrases could be associated with particular
scores, for example, “mild global loss with more pronounced right sided
putamen loss” would be associated with a score of [1,2,1,1]. This can
then be correlated with the clinical findings to aid interpretation.
In this study we chose raters with a range of different backgrounds
and experience levels and found a high level of inter-rater agreement.
This suggests that the proposed scale is likely to be widely applicable in
a clinical setting with a range of reporter expertise.
4.5. Applicability in early disease
All patients in this study had confirmed dementia or Parkinson's
disease. There is increasing interest in imaging patients at earlier stages
(McKeith et al., 2016), where there are some symptoms suggestive of
DLB, but patients have mild cognitive impairment rather than de-
mentia. 123I-Ioflupane striatal uptake can be reduced in such prodromal
DLB, although to a lesser extent than in probable DLB (Kasanuki et al.,
2017). It is likely therefore that the application of any method of image
assessment will be more challenging in prodromal disease. In this study
a significant number of subjects without Lewy body disease had mild
global reduction (but within the normal range). In particular, in phase
two there was one control and two AD subjects with median total scores
between 3 and 4 that had no evidence of Lewy Body pathology at au-
topsy. These cases were incorrectly classified as abnormal using the
Benamer scale. Caution should therefore be exercised in regarding the
appearance of subtle decrease as a reliable sign of early disease. Not-
withstanding the challenges of optimum threshold setting, the method
described here could be applicable to research into early disease.
4.6. Equipment and processing
The images in this study were acquired on a three headed camera.
At the time of the original study (around 2000) this provided image
quality in advance of equipment in routine clinical use. Nowadays
imaging with a dual headed camera is most common in clinical prac-
tice. However, it is likely that the reconstruction method is more re-
levant in terms of image resolution and visual image appearance. For
this study images were processed with filtered back projection and the
resolution and appearance was similar to that used in our centre in
routine clinical practice using a dual headed camera. Recent advances
in image processing using iterative reconstruction can affect image
appearance, particularly if resolution recovery, attenuation and scatter
correction are employed. These methods can particularly affect the
visual appearance of the background. The colour look up table for
display can also have an impact on visual assessment. As with any vi-
sual rating scale, local application of the scale proposed here will need
to take into account the particular equipment and processing used.
Depending on the method used, this caveat will also apply to semi-
quantitative methods.
4.7. Conclusion
A rating scale is proposed based on autopsy confirmed diagnoses that
captures in a straightforward way the visual appearance of 123I-Ioflupane
scans. In this relatively small study, it is demonstrated to have high ac-
curacy in differentiating Lewy Body disease from non-Lewy Body disease
cases and it offers potential advantages over existing visual rating scales.
Further work is warranted to explore the applicability of the rating
method in larger groups of subjects and in a range of different contexts.
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